Abbott Reports First-Quarter 2021 Results

 
 

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2021 .

 
  • First-quarter sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis, which excludes the impact of foreign exchange.
  •  
  • First-quarter GAAP diluted EPS was $1.00 and adjusted diluted EPS, which excludes specified items, was $1.32 , reflecting 103.1 percent growth versus the prior year. 1
  •  
  • Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of at least $3.74 . Projected full-year adjusted diluted EPS from continuing operations of at least $5.00 remains unchanged and reflects growth of more than 35 percent versus the prior year. 2
  •  
  • Global COVID-19 testing-related sales were $2.2 billion in the first quarter, led by combined sales of $1.8 billion from Abbott's BinaxNOW , Panbio and ID NOW rapid testing platforms.
  •  
  • First-quarter sales increased 7.6 percent on a reported basis and 5.7 percent on an organic basis, excluding COVID-19 testing-related sales.
  •  
  • In January, the U.S. Centers for Medicare & Medicaid Services expanded reimbursement coverage eligibility for Abbott's revolutionary MitraClip device, which significantly increases the number of people who can benefit from this market-leading, minimally invasive heart device.
  •  
  • In March, Abbott announced the U.S. launch of NeuroSphere Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed.
  •  
  • In April, Abbott announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of its BinaxNOW COVID-19 Ag Self Test for individuals with or without symptoms and without the need of a prescription.
  •  

"We're off to a very strong start to the year, with all four of our major businesses achieving strong growth," said Robert B. Ford , president and chief executive officer, Abbott. "We're particularly pleased with the growing momentum of several recently launched products and continue to forecast more than 35 percent EPS growth for the year."

 

  FIRST-QUARTER BUSINESS OVERVIEW
  Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.  

 

  Following are sales by business segment and commentary for the first quarter 2021:  

 

   Total Company
 
($ in millions)

 
 
                                                                                                                                  
 
 
 
 
 
 
 
 
 

   % Change vs. 1Q20   

 
 
 
 

   Sales 1Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total *   

 
 
 

  3,838  

 
 
 

  6,618  

 
 
 

  10,456  

 
 
 

  34.4  

 
 
 

  35.9  

 
 
 

  35.3  

 
 
 

  34.4  

 
 
 

  32.0  

 
 
 

  32.9  

 
 

  Nutrition  

 
 
 

  836  

 
 
 

  1,200  

 
 
 

  2,036  

 
 
 

  3.0  

 
 
 

  9.8  

 
 
 

  6.9  

 
 
 

  3.0  

 
 
 

  9.0  

 
 
 

  6.4  

 
 

  Diagnostics  

 
 
 

  1,641  

 
 
 

  2,373  

 
 
 

  4,014  

 
 
 

  104.4  

 
 
 

  131.9  

 
 
 

  119.8  

 
 
 

  104.4  

 
 
 

  122.9  

 
 
 

  114.8  

 
 

  Established Pharmaceuticals  

 
 
 

  --  

 
 
 

  1,070  

 
 
 

  1,070  

 
 
 

  n/a  

 
 
 

  2.5  

 
 
 

  2.5  

 
 
 

  n/a  

 
 
 

  6.2  

 
 
 

  6.2  

 
 

  Medical Devices  

 
 
 

  1,351  

 
 
 

  1,969  

 
 
 

  3,320  

 
 
 

  9.6  

 
 
 

  15.6  

 
 
 

  13.1  

 
 
 

  9.6  

 
 
 

  8.2  

 
 
 

  8.8  

 
 
 
 
      
 
 

  * Total Q1 2021 Abbott sales from continuing operations include Other Sales of approximately $16 million.  

 
 
 

  n/a = Not Applicable.  

 
 
 

  Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate,
by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year
foreign exchange rates.
 

 
 
 

First-quarter 2021 worldwide sales of $10.5 billion increased 35.3 percent on a reported basis and 32.9 percent on an organic basis.

 

   Nutrition
 
($ in millions)

 
 
                                                                                            
 
 
 
 
 
 
 
 
 

   % Change vs. 1Q20   

 
 
 
 

   Sales 1Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 

  836  

 
 
 

  1,200  

 
 
 

  2,036  

 
 
 

  3.0  

 
 
 

  9.8  

 
 
 

  6.9  

 
 
 

  3.0  

 
 
 

  9.0  

 
 
 

  6.4  

 
 

  Pediatric  

 
 
 

  508  

 
 
 

  558  

 
 
 

  1,066  

 
 
 

  (1.8)  

 
 
 

  (2.3)  

 
 
 

  (2.1)  

 
 
 

  (1.8)  

 
 
 

  (3.1)  

 
 
 

  (2.5)  

 
 

  Adult  

 
 
 

  328  

 
 
 

  642  

 
 
 

  970  

 
 
 

  11.4  

 
 
 

  23.1  

 
 
 

  18.9  

 
 
 

  11.4  

 
 
 

  22.1  

 
 
 

  18.3  

 
 
 

Worldwide Nutrition sales increased 6.9 percent on a reported basis and 6.4 percent on an organic basis in the first quarter. Strong performance of Ensure ® , Abbott's market-leading complete and balanced nutrition brand, and Glucerna ® , Abbott's market-leading diabetes nutrition brand, led to global Adult Nutrition sales growth of 18.9 percent on a reported basis and 18.3 percent on an organic basis. In Pediatric Nutrition, sales growth was negatively impacted by a difficult comparison versus the first quarter of 2020 when consumers increased purchases in advance of stay-at-home directives as a result of COVID-19.

 

   Diagnostics
 
($ in millions)

 
 
                                                                                                                                  
 
 
 
 
 
 
 
 
 

   % Change vs. 1Q20   

 
 
 
 

   Sales 1Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 

  1,641  

 
 
 

  2,373  

 
 
 

  4,014  

 
 
 

  104.4  

 
 
 

  131.9  

 
 
 

  119.8  

 
 
 

  104.4  

 
 
 

  122.9  

 
 
 

  114.8  

 
 

  Core Laboratory  

 
 
 

  271  

 
 
 

  911  

 
 
 

  1,182  

 
 
 

  1.9  

 
 
 

  26.1  

 
 
 

  19.6  

 
 
 

  1.9  

 
 
 

  21.3  

 
 
 

  16.1  

 
 

  Molecular  

 
 
 

  175  

 
 
 

  272  

 
 
 

  447  

 
 
 

  168.7  

 
 
 

  267.0  

 
 
 

  220.9  

 
 
 

  168.7  

 
 
 

  250.2  

 
 
 

  212.0  

 
 

  Point of Care  

 
 
 

  92  

 
 
 

  37  

 
 
 

  129  

 
 
 

  (11.4)  

 
 
 

  7.8  

 
 
 

  (6.6)  

 
 
 

  (11.4)  

 
 
 

  3.8  

 
 
 

  (7.6)  

 
 

  Rapid Diagnostics  

 
 
 

  1,103  

 
 
 

  1,153  

 
 
 

  2,256  

 
 
 

  199.7  

 
 
 

  500.6  

 
 
 

  302.8  

 
 
 

  199.7  

 
 
 

  477.7  

 
 
 

  295.0  

 
 
 

Worldwide Diagnostics sales increased 119.8 percent on a reported basis in the first quarter and increased 114.8 percent on an organic basis. Strong growth in the quarter was driven by demand for Abbott's portfolio of COVID-19 diagnostics tests across its rapid and lab-based platforms. Global COVID-19 testing-related sales were $2.2 billion in the first quarter, led by combined sales of $1.8 billion from Abbott's BinaxNOW, Panbio and ID NOW rapid testing platforms.

 

Excluding COVID-19 testing-related sales, Core Laboratory Diagnostics sales increased 10.7 percent and Molecular Diagnostics sales increased 31.5 percent on an organic basis in the first quarter. 3

 

   Established Pharmaceuticals
 
($ in millions)

 
 
                                                                                            
 
 
 
 
 
 
 
 
 

   % Change vs. 1Q20   

 
 
 
 

   Sales 1Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 

  --  

 
 
 

  1,070  

 
 
 

  1,070  

 
 
 

  n/a  

 
 
 

  2.5  

 
 
 

  2.5  

 
 
 

  n/a  

 
 
 

  6.2  

 
 
 

  6.2  

 
 

  Key Emerging Markets  

 
 
 

  --  

 
 
 

  821  

 
 
 

  821  

 
 
 

  n/a  

 
 
 

  1.0  

 
 
 

  1.0  

 
 
 

  n/a  

 
 
 

  6.7  

 
 
 

  6.7  

 
 

  Other  

 
 
 

  --  

 
 
 

  249  

 
 
 

  249  

 
 
 

  n/a  

 
 
 

  7.8  

 
 
 

  7.8  

 
 
 

  n/a  

 
 
 

  4.2  

 
 
 

  4.2  

 
 
 

Established Pharmaceuticals sales increased 2.5 percent on a reported basis in the first quarter and increased 6.2 percent on an organic basis.

 

Key Emerging Markets include India , Brazil , Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 1.0 percent on a reported basis in the quarter and increased 6.7 percent on an organic basis. Organic sales growth was led by strong growth across several geographies, including China , India and Brazil.

 

Other sales increased 7.8 percent on a reported basis in the quarter and increased 4.2 percent on an organic basis.

 

   Medical Devices
 
($ in millions)

 
 
                                                                                                                                                                                           
 
 
 
 
 
 
 
 
 

   % Change vs. 1Q20   

 
 
 
 

   Sales 1Q21   

 
 
 

   Reported   

 
 
 

   Organic   

 
 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 
 

   U.S.   

 
 
 

   Int'l   

 
 
 

   Total   

 
 

   Total   

 
 
 

  1,351  

 
 
 

  1,969  

 
 
 

  3,320  

 
 
 

  9.6  

 
 
 

  15.6  

 
 
 

  13.1  

 
 
 

  9.6  

 
 
 

  8.2  

 
 
 

  8.8  

 
 

  Rhythm Management  

 
 
 

  241  

 
 
 

  278  

 
 
 

  519  

 
 
 

  5.6  

 
 
 

  13.4  

 
 
 

  9.6  

 
 
 

  5.6  

 
 
 

  6.1  

 
 
 

  5.8  

 
 

  Electrophysiology  

 
 
 

  179  

 
 
 

  252  

 
 
 

  431  

 
 
 

  9.3  

 
 
 

  12.3  

 
 
 

  11.0  

 
 
 

  9.3  

 
 
 

  5.5  

 
 
 

  7.1  

 
 

  Heart Failure  

 
 
 

  145  

 
 
 

  49  

 
 
 

  194  

 
 
 

  (4.7)  

 
 
 

  (4.3)  

 
 
 

  (4.6)  

 
 
 

  (4.7)  

 
 
 

  (10.8)  

 
 
 

  (6.2)  

 
 

  Vascular  

 
 
 

  219  

 
 
 

  416  

 
 
 

  635  

 
 
 

  (4.7)  

 
 
 

  5.4  

 
 
 

  1.7  

 
 
 

  (4.7)  

 
 
 

  (0.4)  

 
 
 

  (2.0)  

 
 

  Structural Heart  

 
 
 

  169  

 
 
 

  208  

 
 
 

  377  

 
 
 

  24.3  

 
 
 

  14.3  

 
 
 

  18.6  

 
 
 

  24.3  

 
 
 

  6.7  

 
 
 

  14.2  

 
 

  Neuromodulation  

 
 
 

  145  

 
 
 

  39  

 
 
 

  184  

 
 
 

  6.1  

 
 
 

  (1.4)  

 
 
 

  4.4  

 
 
 

  6.1  

 
 
 

  (8.3)  

 
 
 

  2.8  

 
 

  Diabetes Care  

 
 
 

  253  

 
 
 

  727  

 
 
 

  980  

 
 
 

  35.7  

 
 
 

  28.3  

 
 
 

  30.2  

 
 
 

  35.7  

 
 
 

  19.5  

 
 
 

  23.6  

 
 
 

Worldwide Medical Devices sales increased 13.1 percent on a reported basis in the first quarter and increased 8.8 percent on an organic basis. Strong growth in the quarter was driven by continued recovery from the COVID-19 pandemic. In Diabetes Care, sales of FreeStyle ® Libre and Libre Sense were $829 million in the quarter. FreeStyle Libre now has more than 3 million users worldwide.

 

  ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects 2021 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of at least $3.74 . Abbott forecasts specified items for the full-year 2021 of $1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $5.00 for full-year 2021.

 

  ABBOTT DECLARES 389 TH CONSECUTIVE QUARTERLY DIVIDEND  
On Feb. 19, 2021 , the board of directors of Abbott declared the company's quarterly dividend of $0.45 per share. Abbott's cash dividend is payable May 17, 2021 to shareholders of record at the close of business on April 15, 2021 .

 

Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

 

  About Abbott:  
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

 

Abbott will live webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8:30 a.m. Central time today. An archived edition of the webcast will be available later that day.  
 

 

   Private Securities Litigation Reform Act of 1995 —
  A Caution Concerning Forward-Looking Statements  

 

  Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020 , and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.    

 

  1 First-quarter 2021 diluted EPS from continuing operations on a GAAP basis reflects 233.3 percent growth.
2 Full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of at least 50 percent versus the prior year.
3 Excluding COVID-19 testing-related sales, Core Laboratory Diagnostics sales increased 14.1 percent and Molecular Diagnostics sales increased 33.9 percent on a reported basis in the first quarter.

 

 

 
 
                                                                                                                                                                                                                                                                                                                  
 

  Abbott Laboratories and Subsidiaries  

 

  Condensed Consolidated Statement of Earnings  

 

  First Quarter Ended March 31, 2021 and 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

   1Q21   

 
 
 

   1Q20   

 
 
 

   %
Change
 
 

 
 
 

  Net Sales  

 
 
 

  $10,456  

 
 
 

  $7,726  

 
 
 

  35.3  

 
 
 
 
 
 
 
 
 
 
 

  Cost of products sold, excluding amortization expense  

 
 
 

  4,401  

 
 
 

  3,281  

 
 
 

  34.1  

 
 
 

  Amortization of intangible assets  

 
 
 

  509  

 
 
 

  561  

 
 
 

  (9.2)  

 
 
 

  Research and development  

 
 
 

  654  

 
 
 

  578  

 
 
 

  13.3  

 
 
 

  Selling, general, and administrative  

 
 
 

  2,783  

 
 
 

  2,548  

 
 
 

  9.2  

 
 
 

  Total Operating Cost and Expenses  

 
 
 

  8,347  

 
 
 

  6,968  

 
 
 

  19.8  

 
 
 
 
 
 
 
 
 
 
 

  Operating Earnings  

 
 
 

  2,109  

 
 
 

  758  

 
 
 

  178.0  

 
 
 
 
 
 
 
 
 
 
 

  Interest expense, net  

 
 
 

  124  

 
 
 

  121  

 
 
 

  2.2  

 
 
 

  Net foreign exchange (gain) loss  

 
 
 

  3  

 
 
 

  5  

 
 
 

  (44.7)  

 
 
 

  Other (income) expense, net  

 
 
 

  (61)  

 
 
 

  (1)  

 
 
 

  n/m  

 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  2,043  

 
 
 

  633  

 
 
 

  222.7  

 
 
 
 
 
 
 
 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

  250  

 
 
 

  89  

 
 
 

  180.6  

 
 

  1)  

 
 

  Earnings from Continuing Operations  

 
 
 

  1,793  

 
 
 

  544  

 
 
 

  229.5  

 
 
 
 
 
 
 
 
 
 
 

  Earnings from Discontinued Operations, net of taxes  

 
 
 

  --  

 
 
 

  20  

 
 
 

  n/m  

 
 
 
 
 
 
 
 
 
 
 

  Net Earnings  

 
 
 

  $1,793  

 
 
 

  $564  

 
 
 

  217.8  

 
 
 
 
 
 
 
 
 
 
 

  Earnings from Continuing Operations, excluding  

 
 
 
 
 
 
 
 
 

  Specified Items, as described below  

 
 
 

  $2,368  

 
 
 

  $1,162  

 
 
 

  103.8  

 
 

  2)  

 
 
 
 
 
 
 
 
 
 

  Diluted Earnings per Common Share from:  

 
 
 
 
 
 
 
 
 

  Continuing Operations  

 
 
 

  $1.00  

 
 
 

  $0.30  

 
 
 

  233.3  

 
 
 

  Discontinued Operations  

 
 
 

  --  

 
 
 

  0.01  

 
 
 

  n/m  

 
 
 

  Total  

 
 
 

  $1.00  

 
 
 

  $0.31  

 
 
 

  222.6  

 
 
 
 
 
 
 
 
 
 
 

  Diluted Earnings per Common Share from Continuing  

 
 
 
 
 
 
 
 
 

  Operations, excluding Specified Items, as described below  

 
 
 

  $1.32  

 
 
 

  $0.65  

 
 
 

  103.1  

 
 

  2)  

 
 
 
 
 
 
 
 
 
 

  Average Number of Common Shares Outstanding  

 
 
 
 
 
 
 
 
 

  Plus Dilutive Common Stock Options  

 
 
 

  1,792  

 
 
 

  1,781  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                
 

  NOTES:  

 
 

  See tables titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations" for an explanation of certain non-GAAP financial information.  

 
 

  n/m = Percent change is not meaningful.  

 
 

  See footnotes on the following table.  

 
 
 
 

  1)  

 
 

  2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $80 million in excess tax benefits associated with share-based compensation.  

 
 
 
 

  2)  

 
 

  2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $575 million, or $0.32 per share, for intangible amortization and other net expenses primarily associated with certain litigation, acquisitions and restructuring actions.  

 
 
 
 
 

  2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $618 million, or $0.35 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.  

 
 
 

 

 
 
                                                                                                                                                                                                                    
 

  Abbott Laboratories and Subsidiaries  

 

  Non-GAAP Reconciliation of Financial Information From Continuing Operations  

 

  First Quarter Ended March 31, 2021 and 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

   1Q21   

 
 
 
 

   As
Reported
(GAAP)
 
 

 
 
 

   Specified
Items
 
 

 
 
 

   As
Adjusted
 
 

 
 
 

   % to
Sales
 
 

 
 
 
 
 
 
 
 
 
 
 

  Intangible Amortization  

 
 
 

   $            509   

 
 
 

  $     (509)  

 
 
 

   $          --   

 
 
 
 

  Gross Margin  

 
 
 

   5,546   

 
 
 

  549  

 
 
 

   6,095   

 
 
 

  58.3%  

 
 

  R&D  

 
 
 

   654   

 
 
 

  (28)  

 
 
 

   626   

 
 
 

  6.0%  

 
 

  SG&A  

 
 
 

   2,783   

 
 
 

  (154)  

 
 
 

   2,629   

 
 
 

  25.1%  

 
 

  Other (income) expense, net  

 
 
 

   (61)   

 
 
 

  (12)  

 
 
 

   (73)   

 
 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

   2,043   

 
 
 

  743  

 
 
 

   2,786   

 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

   250   

 
 
 

  168  

 
 
 

   418   

 
 
 
 

  Earnings from Continuing Operations  

 
 
 

   1,793   

 
 
 

  575  

 
 
 

   2,368   

 
 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 

   $1.00   

 
 
 

  $0.32  

 
 
 

   $1.32   

 
 
 
 
 
 

  Specified items reflect intangible amortization expense of $509 million and other net expenses of $234 million, primarily associated with certain litigation, acquisitions, restructuring actions and other expenses. See tables titled "Details of Specified Items" for additional details regarding specified items.  

 
 
 
 
 

   1Q20   

 
 
 
 

   As
Reported
(GAAP)
 
 

 
 
 

   Specified
Items
 
 

 
 
 

   As
Adjusted
 
 

 
 
 

   % to
Sales
 
 

 
 
 
 
 
 
 
 
 
 
 

  Intangible Amortization  

 
 
 

   $            561   

 
 
 

  $      (561)  

 
 
 

   $          --   

 
 
 
 

  Gross Margin  

 
 
 

   3,884   

 
 
 

  599  

 
 
 

   4,483   

 
 
 

  58.0%  

 
 

  R&D  

 
 
 

   578   

 
 
 

  (15)  

 
 
 

   563   

 
 
 

  7.3%  

 
 

  SG&A  

 
 
 

   2,548   

 
 
 

  (58)  

 
 
 

   2,490   

 
 
 

  32.2%  

 
 

  Other (income) expense, net  

 
 
 

   (1)   

 
 
 

  (42)  

 
 
 

   (43)   

 
 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

   633   

 
 
 

  714  

 
 
 

   1,347   

 
 
 
 

  Tax expense on Earnings from Continuing Operations  

 
 
 

   89   

 
 
 

  96  

 
 
 

   185   

 
 
 
 

  Earnings from Continuing Operations  

 
 
 

   544   

 
 
 

  618  

 
 
 

   1,162   

 
 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 

   $0.30   

 
 
 

  $0.35  

 
 
 

   $0.65   

 
 
 
 
 

  Specified items reflect intangible amortization expense of $561 million and other expenses of $153 million, primarily associated with acquisitions, restructuring actions and other expenses. See tables titled "Details of Specified Items" for additional details regarding specified items.  

 
 
 

A reconciliation of the first-quarter tax rates for continuing operations for 2021 and 2020 is shown below:

 
 
                                                                        
 
 
 
 

   1Q21   

 
 

  ($ in millions)  

 
 
 

   Pre-Tax
Income
 
 

 
 
 

   Taxes on
Earnings
 
 

 
 
 

   Tax
Rate
 
 

 
 

   As reported (GAAP)   

 
 
 

   $2,043   

 
 
 

   $         250   

 
 
 

   12.2%   

 
 

  Specified items  

 
 
 

  743  

 
 
 

  168  

 
 
 
 

   Excluding specified items   

 
 
 

   $2,786   

 
 
 

   $418   

 
 
 

   15.0%   

 
 
 
 
 
 
 
 
 
 
 
 
 

   1Q20   

 
 

  ($ in millions)  

 
 
 

   Pre-Tax
Income
 
 

 
 
 

   Taxes on
Earnings
 
 

 
 
 

   Tax
Rate
 
 

 
 

   As reported (GAAP)   

 
 
 

   $633   

 
 
 

   $89   

 
 
 

   14.0%   

 
 

  Specified items  

 
 
 

  714  

 
 
 

  96  

 
 
 
 

   Excluding specified items   

 
 
 

   $1,347   

 
 
 

   $185   

 
 
 

   13.7%   

 
 
 
 
    
 
 
 

  1)  

 
 

  2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $80 million in excess tax benefits associated with share-based compensation.  

 
 
 

 

 
 
                                                                                                                          
 

  Abbott Laboratories and Subsidiaries  

 

  Details of Specified Items  

 

  First Quarter Ended March 31, 2021  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

  Acquisition or
Divestiture-
related (a)
 

 
 
 

  Restructuring
and Cost
Reduction
Initiatives (b)
 

 
 
 

  Intangible
Amortization
 

 
 
 

  Other (c)  

 
 
 

  Total
Specifieds
 

 
 
 

  Gross Margin  

 
 
 

  $               19  

 
 
 

  $              19  

 
 
 

  $           509  

 
 
 

  2  

 
 
 

  $       549  

 
 
 

  R&D  

 
 
 

  (2)  

 
 
 

  --  

 
 
 

  --  

 
 
 

  (26)  

 
 
 

  (28)  

 
 
 

  SG&A  

 
 
 

  (13)  

 
 
 

  (1)  

 
 
 

  --  

 
 
 

  (140)  

 
 
 

  (154)  

 
 
 

  Other (income) expense, net  

 
 
 

  --  

 
 
 

  1  

 
 
 

  --  

 
 
 

  (13)  

 
 
 

  (12)  

 
 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  $               34  

 
 
 

  $              19  

 
 
 

  $           509  

 
 
 

  $      181  

 
 
 

  743  

 
 
 

  Tax expense on Earnings from Continuing Operations (d)  

 
 
 
 
 
 
 
 
 
 
 

  168  

 
 
 

  Earnings from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $       575  

 
 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $      0.32  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 

  The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations."  

 
 
 

  a)  

 
 

  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.  

 
 

  b)  

 
 

  Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.  

 
 

  c)  

 
 

  Other primarily relates to the net costs related to certain litigation, the acquisition of a research and development asset, and the impairment of an equity investment.  

 
 

  d)  

 
 

  Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.  

 
 
 

 

 
 
                                                                                                     
 

  Abbott Laboratories and Subsidiaries  

 

  Details of Specified Items  

 

  First Quarter Ended March 31, 2020  

 

  (in millions, except per share data)  

 

  (unaudited)  

 
 
 
 
 

  Acquisition or
Divestiture-
related (a)
 

 
 
 

  Restructuring
and Cost
Reduction
Initiatives (b)
 

 
 
 

  Intangible
Amortization
 

 
 
 

  Other (c)  

 
 
 

  Total
Specifieds
 

 
 

  Gross Margin  

 
 
 

  $               23  

 
 
 

  $              15  

 
 
 

  $           561  

 
 
 

  $         --  

 
 
 

  $       599  

 
 

  R&D  

 
 
 

  (4)  

 
 
 

  (6)  

 
 
 

  --  

 
 
 

  (5)  

 
 
 

  (15)  

 
 

  SG&A  

 
 
 

  (28)  

 
 
 

  (30)  

 
 
 

  --  

 
 
 

  --  

 
 
 

  (58)  

 
 

  Other (income) expense, net  

 
 
 

  2  

 
 
 

  --  

 
 
 

  --  

 
 
 

  (44)  

 
 
 

  (42)  

 
 

  Earnings from Continuing Operations before taxes  

 
 
 

  $               53  

 
 
 

  $              51  

 
 
 

  $           561  

 
 
 

  $        49  

 
 
 

  714  

 
 

  Tax expense on Earnings from Continuing Operations (d)  

 
 
 
 
 
 
 
 
 
 
 

  96  

 
 

  Earnings from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $       618  

 
 

  Diluted Earnings per Share from Continuing Operations  

 
 
 
 
 
 
 
 
 
 
 

  $      0.35  

 
 
 
 
            
 
 
 

  The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information From Continuing Operations."  

 
 
 

  a)  

 
 

  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired business and include expenditures for retention, severance, and the integration of systems, processes and business activities.  

 
 

  b)  

 
 

  Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.  

 
 

  c)  

 
 

  Other primarily relates to the impairment of an investment.  

 
 

  d)  

 
 

  Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.  

 
 
 

 

 

 Cision View original content: https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2021-results-301272437.html  

 

SOURCE Abbott

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×